Business
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. Lead author on the poster is Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and th
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. Lead author on the poster is Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, and the principal investigator of the Phase 1 clinical trial of Anixa's ovarian cancer CAR-T immunotherapy.","length":664,"tagName":"p"},{"type":"image","alt":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4B69KZz1nJO8NbFw7Kh3Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/602982/ITUS_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Title: Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)","length":198,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Developmental Therapeutics—Immunotherapy","length":54,"tagName":"p"}]},{"val":[{"type":"text","content":"Session Type: Poster Session","length":33,"tagName":"p"}]},{"val":[{"type":"text","content":"Date & Time: June 2, 2025, 1:30 PM – 4:30 PM CT","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract ID: TPS2682","length":25,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":366,"olType":false},{"type":"text","content":"About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused o...